Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD2 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Nebraska Medical Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
PD2 siRNA is a small interfering RNA designed to silence the expression of the Pancreatic Differentiation 2 (PD2) gene, also known as PAF1 (RNA polymerase II-associated factor 1). PD2/PAF1 is a component of the PAF complex, which plays a critical role in transcriptional elongation, histone modification, and mRNA processing. In the context of oncology, particularly pancreatic ductal adenocarcinoma (PDAC), PD2 is frequently overexpressed and is associated with the maintenance of cancer stem cells and the promotion of cell proliferation and metastasis. By specifically targeting and degrading PD2 mRNA, this siRNA approach aims to inhibit the oncogenic signaling pathways mediated by the PAF complex, thereby reducing tumor growth and potentially enhancing the sensitivity of cancer cells to chemotherapy.
- Other names
- siRNA targeting PD2siRNA targeting PAF1
02
Targets
Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on PD2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD2 siRNA.